In particular, the molecular biological characteristics of colorectal cancer have been determined, and the choice of treatment such as EGFR inhibitors, BRAF inhibitors, angiogenesis inhibitors, and immune checkpoint inhibitors differs in clinical practice depending on the presence or absence of KRAS mutation, BRAF mutation, and microsatellite instability (2). The gene discussed is BRAF; the disease is colorectal cancer.